Prelude Therapeutics (PRLD) vs Turn Therapeutics (TTRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Prelude Therapeutics (PRLD) has outperformed Turn Therapeutics (TTRX) over the past year, gaining 173.2% versus a gain of 62.7%. Turn Therapeutics is the larger company by market cap ($358.6 million vs $313.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRLD | TTRX |
|---|---|---|
| Share price | $3.93 | $11.81 |
| Market cap | $313.63M | $358.64M |
| 1-day change | +1.29% | +3.71% |
| YTD return | +33.79% | +189.09% |
| 1-year return | +173.24% | +62.71% |
| 5-year return | -76.14% | — |
| EPS (TTM) | $-0.73 | $-0.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.83 | $16.45 |
| 52-week low | $1.15 | $2.57 |
| Distance from 52-week high | -42.46% | -28.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +134.10% | +111.69% |
| Average volume | 479.23K | 110.43K |
| Shares outstanding | 65.08M | 30.37M |
| Employees | 79 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PRLD has outperformed TTRX by 110.5 percentage points over the past year.
About Prelude Therapeutics
PRLD stock →Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About Turn Therapeutics
TTRX stock →Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PRLD vs TTRX FAQ
Which is bigger, Prelude Therapeutics or Turn Therapeutics?
Turn Therapeutics (TTRX) is larger, with a market capitalization of $358.64M compared with $313.63M for Prelude Therapeutics (PRLD).
Which stock has performed better over the past year, PRLD or TTRX?
PRLD returned +173.24% over the past 12 months, compared with +62.71% for TTRX (price return, excluding dividends). Past performance does not predict future results.
Are Prelude Therapeutics and Turn Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.